Raymond James sets $27 target for Regenxbio stock
James initiated coverage on Regenxbio Inc . (NASDAQ:RGNX), bestowing an Outperform rating and setting a price target of $27.00 for the biotechnology company's shares. The firm's endorsement comes with ...
Gateshead teenager first in the UK to be recruited to heart failure trial after family's 'double blow'
Robert Davidson is the first UK patient recruited to a new medical trial looking to support children with heart failure ...
Wave Life Sciences begins Phase 1 obesity trial
CAMBRIDGE, Mass. - Wave Life Sciences Ltd . (NASDAQ:WVE), a clinical-stage biotechnology company with a market capitalization of $1.87 billion, has announced the commencement of its Phase 1 INLIGHT ...
stmdailynews17h
Blizzard Entertainment Raises Over $2 Million for CureDuchenne: A Tribute to Community and Legacy
Blizzard Entertainment and World of Warcraft players raised over $2 million for CureDuchenne, honoring Mats Steen, a devoted player lost to Duchenne muscular dystrophy, while promoting awareness and ...
Muscular Dystrophy News17h
Phase 2 trial shows DMD treatment ifetroban boosts heart function
Duchenne muscular dystrophy (DMD) treatment ifetroban led to improvements in measures of heart function in a Phase 2 clinical ...
STAT19h
Remembering a remarkable Duchenne champion
Patient advocate Austin Leclaire, who died Feb. 1, played a pivotal role in spurring the development of the first medicines ...